Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens

Jorge Vela-Ojeda, Miriam America García Ruiz Esparza, Abraham Majluf-Cruz, Jaime García-Chavez, Laura Arcelia Montiel-Cervantes, Elba Reyes-Maldonado, Alvaro Hernandez-Caballero, Maria Guadalupe Rodríguez-González

Research output: Contribution to journalArticle

Abstract

Multiple myeloma (MM) is a disease characterized by antitumoral immune dysfunction. The objective of the present study was to determine lymphocyte subsets (B, T, NK, NKT, iNKT, dendritic cells, and regulatory T cells) in 68 newly diagnosed patients and 113 healthy donors. Lymphocyte subsets were studied in the same patients 6 months after treatment. Pre-treatment values of CD4+ T cells, NK cells, type 2 dendritic cells, and B cells in MM patients were lower than in healthy donors. Forty patients (59%) received MPT treatment and 28 (41%) thal–dex. Patients with no response to treatment, exhibited a decrease in CD4+ T cells and NK cells, as well as an increase in Treg cell numbers. Median DFS and OS was lower in patients not achieving response, in patients having low numbers of NK cells, and higher values of LDH. The number of CD4 T cells, NK, DC2, and B cells at diagnosis is lower in patients with MM. Non-responder patients had lower CD4 and NK, but higher Treg cell values. Patients in which response is not achieved, and those holding lower values of NK cells and higher levels of LDH, have poor DFS and OS.

Original languageEnglish
Pages (from-to)306-312
Number of pages7
JournalInternational Journal of Hematology
Volume110
Issue number3
DOIs
StatePublished - 20 Sep 2019

Fingerprint

Thalidomide
Natural Killer Cells
Cell Count
Survival
Regulatory T-Lymphocytes
Multiple Myeloma
Therapeutics
T-Lymphocytes
Dendritic Cells
B-Lymphocytes
Tissue Donors
B-Lymphocyte Subsets
Natural Killer T-Cells
Lymphocyte Subsets
T-Lymphocyte Subsets

Keywords

  • LDH
  • Myeloma
  • NK cells
  • Prognostic factors
  • Treg cells

Cite this

Vela-Ojeda, J., Esparza, M. A. G. R., Majluf-Cruz, A., García-Chavez, J., Montiel-Cervantes, L. A., Reyes-Maldonado, E., ... Rodríguez-González, M. G. (2019). Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens. International Journal of Hematology, 110(3), 306-312. https://doi.org/10.1007/s12185-019-02679-x
Vela-Ojeda, Jorge ; Esparza, Miriam America García Ruiz ; Majluf-Cruz, Abraham ; García-Chavez, Jaime ; Montiel-Cervantes, Laura Arcelia ; Reyes-Maldonado, Elba ; Hernandez-Caballero, Alvaro ; Rodríguez-González, Maria Guadalupe. / Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens. In: International Journal of Hematology. 2019 ; Vol. 110, No. 3. pp. 306-312.
@article{54475ea96667453d9006c5796ab8f7e3,
title = "Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens",
abstract = "Multiple myeloma (MM) is a disease characterized by antitumoral immune dysfunction. The objective of the present study was to determine lymphocyte subsets (B, T, NK, NKT, iNKT, dendritic cells, and regulatory T cells) in 68 newly diagnosed patients and 113 healthy donors. Lymphocyte subsets were studied in the same patients 6 months after treatment. Pre-treatment values of CD4+ T cells, NK cells, type 2 dendritic cells, and B cells in MM patients were lower than in healthy donors. Forty patients (59{\%}) received MPT treatment and 28 (41{\%}) thal–dex. Patients with no response to treatment, exhibited a decrease in CD4+ T cells and NK cells, as well as an increase in Treg cell numbers. Median DFS and OS was lower in patients not achieving response, in patients having low numbers of NK cells, and higher values of LDH. The number of CD4 T cells, NK, DC2, and B cells at diagnosis is lower in patients with MM. Non-responder patients had lower CD4 and NK, but higher Treg cell values. Patients in which response is not achieved, and those holding lower values of NK cells and higher levels of LDH, have poor DFS and OS.",
keywords = "LDH, Myeloma, NK cells, Prognostic factors, Treg cells",
author = "Jorge Vela-Ojeda and Esparza, {Miriam America Garc{\'i}a Ruiz} and Abraham Majluf-Cruz and Jaime Garc{\'i}a-Chavez and Montiel-Cervantes, {Laura Arcelia} and Elba Reyes-Maldonado and Alvaro Hernandez-Caballero and Rodr{\'i}guez-Gonz{\'a}lez, {Maria Guadalupe}",
year = "2019",
month = "9",
day = "20",
doi = "10.1007/s12185-019-02679-x",
language = "Ingl{\'e}s",
volume = "110",
pages = "306--312",
journal = "International Journal of Hematology",
issn = "0925-5710",
number = "3",

}

Vela-Ojeda, J, Esparza, MAGR, Majluf-Cruz, A, García-Chavez, J, Montiel-Cervantes, LA, Reyes-Maldonado, E, Hernandez-Caballero, A & Rodríguez-González, MG 2019, 'Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens', International Journal of Hematology, vol. 110, no. 3, pp. 306-312. https://doi.org/10.1007/s12185-019-02679-x

Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens. / Vela-Ojeda, Jorge; Esparza, Miriam America García Ruiz; Majluf-Cruz, Abraham; García-Chavez, Jaime; Montiel-Cervantes, Laura Arcelia; Reyes-Maldonado, Elba; Hernandez-Caballero, Alvaro; Rodríguez-González, Maria Guadalupe.

In: International Journal of Hematology, Vol. 110, No. 3, 20.09.2019, p. 306-312.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens

AU - Vela-Ojeda, Jorge

AU - Esparza, Miriam America García Ruiz

AU - Majluf-Cruz, Abraham

AU - García-Chavez, Jaime

AU - Montiel-Cervantes, Laura Arcelia

AU - Reyes-Maldonado, Elba

AU - Hernandez-Caballero, Alvaro

AU - Rodríguez-González, Maria Guadalupe

PY - 2019/9/20

Y1 - 2019/9/20

N2 - Multiple myeloma (MM) is a disease characterized by antitumoral immune dysfunction. The objective of the present study was to determine lymphocyte subsets (B, T, NK, NKT, iNKT, dendritic cells, and regulatory T cells) in 68 newly diagnosed patients and 113 healthy donors. Lymphocyte subsets were studied in the same patients 6 months after treatment. Pre-treatment values of CD4+ T cells, NK cells, type 2 dendritic cells, and B cells in MM patients were lower than in healthy donors. Forty patients (59%) received MPT treatment and 28 (41%) thal–dex. Patients with no response to treatment, exhibited a decrease in CD4+ T cells and NK cells, as well as an increase in Treg cell numbers. Median DFS and OS was lower in patients not achieving response, in patients having low numbers of NK cells, and higher values of LDH. The number of CD4 T cells, NK, DC2, and B cells at diagnosis is lower in patients with MM. Non-responder patients had lower CD4 and NK, but higher Treg cell values. Patients in which response is not achieved, and those holding lower values of NK cells and higher levels of LDH, have poor DFS and OS.

AB - Multiple myeloma (MM) is a disease characterized by antitumoral immune dysfunction. The objective of the present study was to determine lymphocyte subsets (B, T, NK, NKT, iNKT, dendritic cells, and regulatory T cells) in 68 newly diagnosed patients and 113 healthy donors. Lymphocyte subsets were studied in the same patients 6 months after treatment. Pre-treatment values of CD4+ T cells, NK cells, type 2 dendritic cells, and B cells in MM patients were lower than in healthy donors. Forty patients (59%) received MPT treatment and 28 (41%) thal–dex. Patients with no response to treatment, exhibited a decrease in CD4+ T cells and NK cells, as well as an increase in Treg cell numbers. Median DFS and OS was lower in patients not achieving response, in patients having low numbers of NK cells, and higher values of LDH. The number of CD4 T cells, NK, DC2, and B cells at diagnosis is lower in patients with MM. Non-responder patients had lower CD4 and NK, but higher Treg cell values. Patients in which response is not achieved, and those holding lower values of NK cells and higher levels of LDH, have poor DFS and OS.

KW - LDH

KW - Myeloma

KW - NK cells

KW - Prognostic factors

KW - Treg cells

UR - http://www.scopus.com/inward/record.url?scp=85067038595&partnerID=8YFLogxK

U2 - 10.1007/s12185-019-02679-x

DO - 10.1007/s12185-019-02679-x

M3 - Artículo

C2 - 31168767

AN - SCOPUS:85067038595

VL - 110

SP - 306

EP - 312

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -